| 商品名称 | Deferiprone Lipomed |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Iron Overload;beta-Thalassemia |
| 通用名/非专利名称 | deferiprone |
| 活性成分 | Deferiprone |
| 产品号 | EMEA/H/C/004710 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | V03AC02 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | Yes |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2018/09/19 |
| 上市许可开发者/申请人/持有人 | Lipomed GmbH |
| 人用药物治疗学分组 | All other therapeutic products |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2018/07/26 |
| 欧盟委员会决定日期 | 2023/06/26 |
| 修订号 | 7 |
| 治疗适应症 | Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2018/07/27 |
| 最后更新日期 | 2022/07/14 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/deferiprone-lipomed-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/deferiprone-lipomed |